Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program

Thromboembolic risk is higher in women than men with non-valvular atrial fibrillation (NVAF). Published data indicate variability antithrombotic use by gender and region. We analyzed gender-specific treatment patterns Spain rest of Western Europe (rWE) patients NVAF. GLORIA-AF (Phase III) a global, prospective, observational study which enrolled newly diagnosed NVAF CHA2DS2-VAScs ≥ 1 (2014–2016). Analyses were performed comparing treatments rWE. This analysis included 1163 7972 from rWE, respectively. Stroke was both While bleeding pattern similar between genders, lower more females compared to received OACs (95.0% versus 92.4%, d = −0.1078, respectively). Fewer Spanish direct oral anticoagulants (DOACs) (women 32.1%, 25.3%) vitamin-K-antagonists (VKAs) 63.0%, 67.1%) vs. rWE patients. In DOACs (56.0% 44.0%). OAC rates as More Spain, while no difference observed. are the most prescribed due prescription barriers, its remains low for genders VKAs preferred. men. (NCT01468701). El riesgo tromboembólico es mayor en mujeres que varones con fibrilación auricular valvular (FANV). Existen diferencias el uso de anticoagulantes (ACO) según sexo y zona geográfica. Se estudiaron los patrones anticoagulación por España resto Europa Occidental (rEO) pacientes FANV. un estudio observacional prospectivo (fase incluyó diagnóstico reciente FANV CHA2DS2-VASc > (2014-2016). analizó la prescripción rEO. 1.163 7.972 del ictus fue superior tanto como hemorragia tratamiento antitrombótico fueron similares ambos sexos rEO; España, menor estas recibieron más ACO (95,0% 92,4%, –0,1078). En menos directos (ACOD) (mujeres 32,1%, 25,3%) antagonistas vitamina K (AVK) 63,0%, 67,1%), las ACOD (56,0% 44,0%). se emplearon rEO tratadas ACO, mientras hubo sexo. rEO, más. emplean restricciones AVK. Las españolas reciben varones.